Won Seog Kim
Professor, Head of Malignant Lymphoma Center
Samsung Medical Center / Sungkyunkwan University · Seoul, South Korea
Leading Korean lymphoma researcher at Samsung Medical Center. Has contributed significantly to understanding MCL treatment outcomes in Asian populations.
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.
Leukemia & lymphoma · Mar 17, 2026
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Clinical cancer research : an official journal of the American Association for Cancer Research · Mar 2, 2026
Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
PloS one · Jan 1, 2026
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.
Science advances · Dec 5, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis.
Blood advances · Oct 28, 2025
YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.
Blood advances · Oct 14, 2025
Transcriptional Analysis of Effusion-Based Lymphoma Supports a Post-Germinal Center Origin and Specific Inflammatory Signal Background.
Cancers · Sep 12, 2025
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.
Blood research · Aug 15, 2025
A comprehensive analysis of the role of stem cell transplantation in mantle cell lymphoma: real-world data from the Korean Society of Blood and Marrow Transplantation registry: Stem cell transplantation outcomes in mantle cell lymphoma.
Blood research · Aug 13, 2025
Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas.
Cancer immunology, immunotherapy : CII · Jul 12, 2025
Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing.
Archives of medical research · Jun 1, 2025
Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma.
bioRxiv : the preprint server for biology · May 24, 2025
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Clinical lymphoma, myeloma & leukemia · Mar 1, 2025
Real-world assessment to estimate multiple attributes related to treatment cost driver for mantle cell lymphoma in Japan by econometric modeling.
BMC health services research · Jan 27, 2025
Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.
ACG case reports journal · Jan 1, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Blood · May 9, 2024
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Human pathology · Apr 1, 2024
Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma.
Human pathology · Feb 1, 2024